MSMichelle Scurr

Michelle Scurr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle Scurr has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: a case report

    by Claire Ross, Sunita Sharma, Onsy Louca, Michelle Scurr, Andrew Hayes, Ian Judson

    Perivascular epithelioid cell tumors are a family of rare mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. They can originate in any visceral organ or soft tissue and include a range of lesions such as angiomyolipoma, clear cell 'sugar' tumor of the lung, lymphangioleiomyomatosis and clear cell myomelanocytic tumors of the falciparum ligament/ligament teres. Due to their rarity and varied sites and presentation, management of these tumors remains highly challenging.


  • Histology-Driven Chemotherapy in Soft Tissue Sarcomas

    by Michelle Scurr

    Doxorubicin and ifosfamide are the two chemotherapy drugs that have consistently demonstrated activity in “soft tissue sarcoma” (STS). However, STS is not a homogeneous entity but an umbrella term for a diverse group of more than 40 differing subtypes; each with distinct underlying biology, natural history and response to treatments. The accuracy of the histological and in some cases molecular diagnosis is therefore critical to the optimal treatment of these patients. Leiomyosarcomas have been shown to have limited responsiveness to ifosfamide, but both the combination of gemcitabine and docetaxel, and single agent trabectedin have shown considerable activity in this tumour group. Differences in responses to chemotherapy are seen for leiomyosarcomas of different anatomical sites with uterine leiomyosarcoma demonstrating considerable chemo-responsiveness, whereas vascular leiomyosarcomas appearing far less sensitivity. There is considerable variation in the sensitivity of the three main subtypes of liposarcomas, with well-differentiated liposarcomas showing generalised chemo-resistance through to the impressive responses seen anthracyclines and to trabectedin with the myxoid subtype. Angiosarcomas have demonstrated considerable sensitivity to paclitaxel, a drug that has little activity outside of vascular sarcomas, and liposomal doxorubicin appears to have a particular indication in this subtype. Synovial sarcomas appear to have significant sensitivity to ifosfamide, even on re-challenge. On the other hand, there are subtypes that are chemo-resistant, including gastrointestinal stromal tumour, alveolar soft part sarcoma and clear cell sarcoma, and chemotherapy plays no role in their management. Whilst it is obvious that there is a need to find new agents to treat these tumours, there is an imperative to make sure that the studies that evaluate their “efficacy” are designed to determine the efficacy within differing histiotypes through stratification by histological subtype, or enrichment strategies to ensure that “activity” is not diluted by unresponsive or even chemo-resistant tumour types.


  • How to Treat the Ewing's Family of Sarcomas in Adult Patients

    by Michelle Scurr, Ian Judson

    Learning Objectives: After completing this course, the reader will be able to: Describe how ESFT is not only a disease of children, but equally that of young adults.Discuss the established prognostic variables in ESFT and the unresolved controversy surrounding the role of older age in patient outcome.Explain that until large studies, such as the current EuroEwings study, can prospectively define the role of age as a prognostic variable, adult patients with ESFT need to be treated as intensively as younger patients. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com